B. Metzler seel. Sohn & Co. AG Has $1.36 Million Holdings in BioNTech SE (NASDAQ:BNTX)

B. Metzler seel. Sohn & Co. AG boosted its stake in BioNTech SE (NASDAQ:BNTX) by 26.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,959 shares of the company’s stock after buying an additional 2,491 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in BioNTech were worth $1,363,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of BNTX. Jones Financial Companies Lllp lifted its holdings in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares during the period. Quintet Private Bank Europe S.A. grew its holdings in shares of BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE acquired a new stake in shares of BioNTech during the 4th quarter worth about $90,000. GAMMA Investing LLC lifted its holdings in BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new position in BioNTech in the fourth quarter valued at about $137,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Morgan Stanley dropped their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Wells Fargo & Company started coverage on BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective for the company. BMO Capital Markets increased their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Price Performance

BNTX opened at $92.01 on Friday. The company has a fifty day moving average price of $109.42 and a two-hundred day moving average price of $113.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $22.08 billion, a PE ratio of -43.81 and a beta of 0.30. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the company posted $1.90 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis. As a group, analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.